MGNX Stock Recent News
MGNX LATEST HEADLINES
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
Macrogenics (NASDAQ: MGNX ) stock is dropping hard on Friday after the after providing investors with a clinical trial update in its latest earnings report. The news that has investors spooked today has to do with fatalities during Macrogenics' TAMARACK study.
MacroGenics, Inc. (NASDAQ:MGNX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Call Participants Tara Bancroft - TD Cowen Jonathan Chang - Leerink Partners Ashiq Mubarack - Citi Kaveri Pohlman - BTIG Stephen Willey - Stifel John Miller - Evercore Etzer Darout - BMO Capital Markets Mayank Mamtani - B. Riley Securities Silvan Tuerkcan - Citizens JMP Securities Kelsey Goodwin - Guggenheim Partners Peter Lawson - Barclays Operator Good afternoon.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET.
Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024.
MacroGenics, Inc. (NASDAQ:MGNX ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Call Participants Jonathan Chang - Leerink Partners Kelsey Goodwin - Guggenheim Stephen Willey - Stifel Etzer Darout - BMO Capital Markets Yigal Nochomovitz - Citigroup John Miller - Evercore Kaveri Pohlman - BTIG Tara Bancroft - TD Cowen Pete Lawson - Barclays Silvan Tuerkcan - Citizens JMP Operator Good afternoon. We will begin the MacroGenics 2023 Fourth Quarter Corporate Progress and Financial Results Conference Call in just a moment.
MacroGenics (MGNX) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $0.21 per share a year ago.